Page last updated: 2024-11-05

tranexamic acid and 2019 Novel Coronavirus Disease

tranexamic acid has been researched along with 2019 Novel Coronavirus Disease in 12 studies

Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.

Research Excerpts

Excerpt	Relevance	Reference
"Tranexamic acid is a plasmin inhibitor that is used off-label for the treatment of melasma."	3.01	The uses of tranexamic acid in dermatology: a review. ( Kim, KM; Lim, HW, 2023)
"Tranexamic acid (TXA) is an anti-fibrinolytic drug that reduces the conversion of plasminogen to plasmin, which is necessary for SARS-CoV-2 infectivity."	3.01	Tranexamic Acid and Plasminogen/Plasmin Glaring Paradox in COVID-19. ( Al-Gareeb, AI; Al-Harcan, NAH; Al-Kuraishy, HM; Alexiou, A; Batiha, GE, 2023)

Research

Studies (12)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	12 (100.00)	2.80

Authors

Authors	Studies
Kim, KM	1
Lim, HW	1
Wagener, G	1
Goldklang, MP	1
Gerber, A	1
Elisman, K	1
Eiseman, KA	1
Fonseca, LD	1
D'Armiento, JM	1
Al-Kuraishy, HM	1
Al-Gareeb, AI	1
Al-Harcan, NAH	1
Alexiou, A	1
Batiha, GE	1
Benhamou, D	1
Keita, H	1
Ducloy-Bouthors, AS	1
Ogawa, H	1
Asakura, H	1
Muse, IO	1
Montilla, E	1
Gruson, KI	1
Berger, J	1
Kinsey, KE	1
Ganz, E	1
Khalil, S	1
Brustman, L	1
Dorgalaleh, A	1
Baghaipour, MR	1
Tabibian, S	1
Ghazizadeh, F	1
Dabbagh, A	1
Bahoush, G	1
Jazebi, M	1
Bahraini, M	1
Fazeli, A	1
Baghaipour, N	1
Yousefi, F	1
Grewal, E	1
Sutarjono, B	1
Mohammed, I	1
Asserson, DB	1
Sahar, DE	1
Mete Gökmen, N	1
Kuman Tunçel, O	1
Boğatekin, G	1
Bulut, G	1
Demir, S	1
Gelincik, A	1
Tunakan Dalgıç, C	1
Mungan, D	1
Rampotas, A	1
Watson, E	1
Burton, K	1
Hill, QA	1
Pavord, S	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Randomized Controlled Trial of Angiotensin 1-7 (TXA127) for the Treatment of Severe COVID-19[NCT04401423]			Phase 2	22 participants (Actual)	Interventional	2021-02-10	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change of Serum Creatinine

Calculated from baseline (at enrollment) to end of study (NCT04401423)
Timeframe: Day 1 and Day 10

Intervention	mg/dL (Mean)
TXA127	0.92
Placebo	0.70

Mortality

(NCT04401423)
Timeframe: Day 1 to Day 10

Intervention	Participants (Count of Participants)
TXA127	1
Placebo	0

Number of Participants Requiring a Vasopressors

(NCT04401423)
Timeframe: Up to Day 10

Intervention	Participants (Count of Participants)
TXA127	3
Placebo	1

Number of Participants Requiring Dialysis

(NCT04401423)
Timeframe: Up to Day 10

Intervention	Participants (Count of Participants)
TXA127	0
Placebo	0

Number of Participants Requiring Intubation

(NCT04401423)
Timeframe: From Day 1 to Day 10

Intervention	Participants (Count of Participants)
TXA127	3
Placebo	2

Percent Change in Supplemental Oxygen Requirements

(NCT04401423)
Timeframe: Day 1 and Day 10

Intervention	percent change of oxygen (Mean)
TXA127	0.71
Placebo	0.91

Cytokine Levels on the Day 5 of Drug/TXA Administration

(NCT04401423)
Timeframe: Day 5

Intervention	pg/ml (Median)
	Interferon-γ	IL-1β	IL-1Ra	IL-2	IL-4	IL-5	IL-6	IL-8	TNF-α	IL-10	IL-12p40	IL-12p70	IL-13	MCP-1
Placebo	0.78	50.6	7.38	0.91	0.74	0.99	1.34	14.3	42.1	4.19	29.8	1.21	11.4	237
TXA127	0.88	14.4	17.77	0.20	0.09	3.36	12.88	24.5	31.1	2.46	45.40	1.28	10.71	218

Cytokine Levels on the Day of Drug/TXA Administration

(NCT04401423)
Timeframe: Day 1

Intervention	pg/ml (Median)
	Interferon-γ	IL-1β	IL-1Ra	IL-2	IL-4	IL-5	IL-6	IL-8	TNF-α	IL-10	IL-12p40	IL-12p70	IL-13	MCP-1
Placebo	1.0	30.6	7.6	0.37	0.21	1.21	3.35	16.2	45.9	10.8	28.9	0.63	8.5	283
TXA127	1.44	20.7	15.9	0.52	0.41	1.72	9.63	24.4	68.4	12.3	32.4	1.74	9.9	345

Days of Hospital Stay and Drug Administration

(NCT04401423)
Timeframe: Day 1 to Day 10

Intervention	days (Median)
	Length of Hospital Stay	Days of Drug/placebo administration
Placebo	7	5
TXA127	11	4

Reviews

3 reviews available for tranexamic acid and 2019 Novel Coronavirus Disease

Article	Year
The uses of tranexamic acid in dermatology: a review. International journal of dermatology, 2023, Volume: 62, Issue:5 Topics: Antifibrinolytic Agents; COVID-19; Dermatology; Humans; Melanosis; Pandemics; Tranexamic Acid; Treat	2023
Tranexamic Acid and Plasminogen/Plasmin Glaring Paradox in COVID-19. Endocrine, metabolic & immune disorders drug targets, 2023, Volume: 23, Issue:1 Topics: COVID-19; Fibrinolysin; Humans; Plasminogen; SARS-CoV-2; Tranexamic Acid	2023
Coagulation changes and thromboembolic risk in COVID-19 obstetric patients. Anaesthesia, critical care & pain medicine, 2020, Volume: 39, Issue:3 Topics: Anticoagulants; Autoantibodies; Betacoronavirus; Blood Proteins; Cerebrovascular Disorders; Contrain	2020

Trials

1 trial available for tranexamic acid and 2019 Novel Coronavirus Disease

Article	Year
A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1-7 (TXA-127) for the treatment of severe COVID-19. Critical care (London, England), 2022, 07-28, Volume: 26, Issue:1 Topics: Angiotensin I; Antifibrinolytic Agents; Blood Loss, Surgical; COVID-19; Double-Blind Method; Humans;	2022

Other Studies

8 other studies available for tranexamic acid and 2019 Novel Coronavirus Disease

Article	Year
Consideration of Tranexamic Acid Administration to COVID-19 Patients. Physiological reviews, 2020, 10-01, Volume: 100, Issue:4 Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Estrone; Fibrinolysin; Humans; Pandemics; Pneumon	2020
Perioperative management of patients with hip fractures and COVID-19: A single institution's early experiences. Journal of clinical anesthesia, 2020, Volume: 67 Topics: Aged; Aged, 80 and over; Anesthesia, Conduction; Antifibrinolytic Agents; COVID-19; Female; Femoral	2020
Intraoperative coagulopathy during cesarean section as an unsuspected initial presentation of COVID-19: a case report. BMC pregnancy and childbirth, 2020, Aug-24, Volume: 20, Issue:1 Topics: Adult; Antifibrinolytic Agents; Betacoronavirus; Blood Coagulation Disorders; Blood Loss, Surgical;	2020
Gastrointestinal bleeding in a newborn infant with congenital factor X deficiency and COVID-19-A common clinical feature between a rare disorder and a new, common infection. International journal of laboratory hematology, 2020, Volume: 42, Issue:6 Topics: Betacoronavirus; Cesarean Section; Clinical Laboratory Techniques; Consanguinity; Coronavirus Infect	2020
Angioedema, ACE inhibitor and COVID-19. BMJ case reports, 2020, Sep-09, Volume: 13, Issue:9 Topics: Angioedema; Angiotensin-Converting Enzyme Inhibitors; Anti-Allergic Agents; Benzazepines; Betacorona	2020
Can Tranexamic Acid Be Safely Administered during Microsurgery in the Era of COVID-19? Plastic and reconstructive surgery, 2021, 03-01, Volume: 147, Issue:3 Topics: Antifibrinolytic Agents; Blood Loss, Surgical; COVID-19; Humans; Microsurgery; Tranexamic Acid	2021
Psychiatric and Clinical Characteristics of Hereditary Angioedema Patients Who Experienced Attacks During COVID-19. Journal of investigational allergology & clinical immunology, 2021, Jul-26, Volume: 31, Issue:4 Topics: Adult; Angioedemas, Hereditary; Anxiety; COVID-19; Danazol; Female; Humans; Male; Middle Aged; SARS-	2021
A real-world study of immune thrombocytopenia management during the COVID-19 pandemic in the UK. British journal of haematology, 2022, Volume: 196, Issue:2 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Combined M	2022